Skye Bioscience, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the provided text does not give standalone fourth-quarter financial results. The filing was signed March 21, 2024.
Business context
Skye is a clinical-stage biopharmaceutical company developing medicines targeting the endocannabinoid system. Its two principal clinical programs are nimacimab, a peripheral CB1-inhibiting antibody being developed for obesity, and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist eye drop for glaucoma and ocular hypertension. Skye acquired nimacimab through its August 2023 acquisition of Bird Rock Bio.
Financial performance and liquidity
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.82 million | $6.01 million |
| General and administrative expense | $7.85 million | $6.09 million |
| Operating loss | $34.74 million | $18.31 million |
| Net loss | $37.64 million | $19.48 million |
| Basic and diluted loss per share | $5.37 | $8.77 |
| Net cash used in operating activities | $13.95 million | $12.74 million |
There is no meaningful operating margin to assess because Skye had no revenue. The larger FY2023 net loss primarily reflected a $21.22 million non-cash charge for acquired in-process R&D (nimacimab), plus higher G&A and a $1.38 million non-cash debt-conversion inducement charge. The legal-contingency expense fell from $6.21 million in 2022 to a $0.15 million reduction in 2023 after the court revised the attorney-fee award.
At year-end, Skye reported $1.26 million of unrestricted cash and $9.08 million of restricted cash securing an appeal bond; the restricted amount is not freely available for operations. Working capital was negative $2.25 million. Total liabilities were $14.07 million, including a $5.00 million related-party convertible note with a $4.37 million carrying value, 10% stated interest, and an August 18, 2024 maturity unless earlier converted or repaid. The filing reports no material off-balance-sheet arrangements.
Operating cash use increased year over year. Investing activities provided $6.60 million, primarily from the VDL asset sale and cash acquired with Bird Rock; financing activities provided $16.44 million, largely from the August 2023 PIPE and convertible note. Management expects continued significant losses and negative operating cash flow. Although year-end cash was limited, management stated that cash available at issuance would fund operations for at least 12 months, taking account of subsequent financing.
Material changes and subsequent events
- Operating loss rose to $34.74 million from $18.31 million; G&A increased 29% to $7.85 million, while R&D declined 3% to $5.82 million.
- Skye acquired Bird Rock Bio in August 2023, issuing shares valued at approximately $21.61 million; the $21.22 million nimacimab IPR&D charge was expensed because it had no alternative future use.
- Skye completed a 1-for-250 reverse stock split in September 2023 and later increased authorized common shares to 100 million.
- In January and March 2024, Skye completed PIPE financings with combined net proceeds of approximately $83.5 million, which management said would fund planned glaucoma and obesity trials through top-line Phase 2 data. These are subsequent events, not FY2023 operating cash flows.
Outlook, risks and contingencies
- Clinical outlook: SBI-100 OE Phase 2a enrollment was completed in Q1 2024, with data expected in Q2 2024. Management planned a Phase 2b study against standard of care following those results. For nimacimab, Skye planned a Phase 2 obesity study, including monotherapy and combination with a GLP-1 agonist, in 2024; final data were expected in late 2025.
- Clinical and regulatory uncertainty: Neither candidate is approved, and success, timing, safety, efficacy, regulatory approval, commercial acceptance and reimbursement are uncertain. The Phase 1 findings described in the filing do not establish efficacy in the intended patient populations.
- Cunning lawsuit: A jury awarded a former employee economic, non-economic and punitive damages; the company recorded a $6.05 million liability plus $0.23 million accrued interest. Skye appealed, and the filing says the recorded contingency could materially change. A $9.08 million appeal bond is collateralized by restricted cash. Skye is also pursuing up to $5 million of insurance coverage, less the deductible; recovery is not assured.
- SBI-100 controlled-substance exposure: SBI-100 remains Schedule I pending future regulatory action. DEA and state registrations, quotas, security and handling rules, and possible rescheduling could add cost or delay development or launch.
- Funding and dilution: Skye has a substantial loss history and may need more capital. Financing could dilute shareholders; as of March 20, 2024, the filing lists 13.26 million shares underlying outstanding warrants, in addition to options, RSUs and a $5 million convertible note.
- Other key risks: Reliance on third-party manufacturers and CROs, competition, intellectual-property protection and the University of Mississippi SBI-100 license, potential trial delays, and market and supply-chain disruption. The filing identifies no critical audit matters; management reported disclosure controls and internal control over financial reporting effective as of year-end.
Important facts for investors to verify
- Whether the SBI-100 OE Phase 2a results support further trials, and whether nimacimab’s Phase 2 trial starts on the stated schedule and produces persuasive results.
- The current status and potential financial outcome of the Cunning appeal, and whether insurance provides coverage or reimbursement.
- Cash runway after the January and March 2024 financings, including actual trial costs and any restrictions or commitments on financing proceeds.
- The convertible note’s repayment or conversion status, and the potential dilution from outstanding warrants, options, RSUs and future capital raises.
- DEA scheduling, registrations and supply requirements for SBI-100, and the scope and remaining duration of Skye’s licensed and owned patent protection.